| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Giustina, E Bresciani, A R Bussi, A Bollati, C Bonfanti, G Bugari, L Chiesa, G Giustin. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7536207. |
in conclusion, we demonstrated that the large majority of numerous patients with active acromegaly show a decrease in serum gh levels after galanin administration. |
1995-05-12 |
2023-08-12 |
human |
| P P Feuillan, J Jones, J L Ros. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7714111. |
gh every 20 min for 24 h, insulin-like growth factor i (igf-i), igf-binding protein 3, and estradiol (e2) were measured in a 7.3-yr-old girl with precocious puberty due to mccune-albright syndrome (mas) who developed stigmata of early acromegaly and in 9 other mas patients who had no signs of acromegaly. |
1995-05-12 |
2023-08-12 |
Not clear |
| Y Greenman, D Prager, S Melme. The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. Clinical endocrinology. vol 42. issue 2. 1995-05-08. PMID:7704960. |
clinical acromegaly is characterized by dysregulation of somatotroph gh secretion in the presence of high circulating serum igf-i levels. |
1995-05-08 |
2023-08-12 |
Not clear |
| H Kotzmann, M Köller, S Czernin, M Clodi, T Svoboda, M Riedl, G Boltz-Nitulescu, C C Zielinski, A Luge. Effect of elevated growth hormone concentrations on the phenotype and functions of human lymphocytes and natural killer cells. Neuroendocrinology. vol 60. issue 6. 1995-05-02. PMID:7700505. |
long-lasting and pronounced elevation of gh in acromegaly induces significantly enhanced phagocytic activity, but only negligible changes in most patients in lymphocyte phenotype and in the lymphocyte response to pha. |
1995-05-02 |
2023-08-12 |
human |
| A Giustina, M Doga, E Bresciani, A R Bussi, L Chiesa, V Misitano, G Giustin. Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly. Metabolism: clinical and experimental. vol 44. issue 3. 1995-04-12. PMID:7885285. |
infusion of hydrocortisone on the gh response to thyrotropin-releasing hormone (trh) in acromegaly. |
1995-04-12 |
2023-08-12 |
human |
| S Grinspoon, D Clemmons, B Swearingen, A Klibansk. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 3. 1995-04-11. PMID:7533774. |
we, therefore, investigated the sensitivity of serum igfbp-3 levels to detect gh excess in 44 patients with clinical acromegaly and pathologically confirmed somatotroph adenomas, including a cohort of 18 patients with untreated disease evaluated before transsphenoidal surgery and medical therapy. |
1995-04-11 |
2023-08-12 |
Not clear |
| S Grinspoon, D Clemmons, B Swearingen, A Klibansk. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 3. 1995-04-11. PMID:7533774. |
in 11% of untreated patients with clinical findings of acromegaly and a pathologically confirmed adenoma, ig-fbp-3 levels were elevated, although gh was suppressed to less than 2 micrograms/l with glucose. |
1995-04-11 |
2023-08-12 |
Not clear |
| J Bertherat, M T Bluet-Pajot, J Epelbau. Neuroendocrine regulation of growth hormone. European journal of endocrinology. vol 132. issue 1. 1995-03-14. PMID:7850005. |
igf-i and activin are among the factors that regulate gh gene expression at the transcriptional level and may play a role in somatotroph differentiation and proliferation during ontogeny as well as physiological and pathological states such as acromegaly. |
1995-03-14 |
2023-08-12 |
Not clear |
| R Attanasio, R Cozzi, G Oppizzi, D Dallabonzana, I Chiodini, Z Benini, P Orlandi, A Liuzzi, P G Chiodin. Persistence of somatostatinergic tone in acromegaly. European journal of endocrinology. vol 132. issue 1. 1995-03-14. PMID:7850006. |
it is a matter of debate whether hypothalamic somatostatin (srih) secretion in acromegaly is preserved and still regulated by the physiological feedback mechanisms of growth hormone (gh) and insulin-like growth factor i. |
1995-03-14 |
2023-08-12 |
Not clear |
| E Horvath, K Kovacs, B W Scheithauer, R V Lloyd, H S Smyt. Pituitary adenoma with neuronal choristoma (PANCH): composite lesion or lineage infidelity? Ultrastructural pathology. vol 18. issue 6. 1995-03-13. PMID:7855931. |
immunohistochemistry documented growth hormone (gh) in every pa, including those unassociated with clinical acromegaly. |
1995-03-13 |
2023-08-12 |
Not clear |
| A J O'Sullivan, J J Kelly, D M Hoffman, R C Baxter, K K H. Energy metabolism and substrate oxidation in acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 2. 1995-03-10. PMID:7852509. |
we conclude that 1) the chronic effects of gh excess on substrate oxidation differ from the short term effects of gh administration; 2) impaired insulin action in acromegaly extends to effects on energy expenditure; and 3) igf-i may be an important regulator of substrate oxidation in acromegaly. |
1995-03-10 |
2023-08-12 |
human |
| L Saccà, A Cittadini, S Fazi. Growth hormone and the heart. Endocrine reviews. vol 15. issue 5. 1995-03-07. PMID:7843068. |
in acromegaly, the functional consequences of gh excess initially prevail (hyperkinetic syndrome), followed by alterations of cardiac function when myocardial hypertrophy develops. |
1995-03-07 |
2023-08-12 |
Not clear |
| J Oscarsson, O Wiklund, K E Jakobsson, B Petruson, B A Bengtsso. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clinical endocrinology. vol 41. issue 5. 1995-02-23. PMID:7828349. |
acromegaly is a rare disorder characterized by over-secretion of gh, most often because of a pituitary adenoma. |
1995-02-23 |
2023-08-12 |
Not clear |
| b' G M Prelevi\\xc4\\x8. [Clinical use of octreotide (Sandostatin) in endocrinology]. Medicinski pregled. vol 46. issue 9-10. 1995-01-19. PMID:7997211.' |
in patients with acromegaly octreotide treatment results in decrease of growth hormone (gh) and igf-i together with tumour shrinkage and clinical improvement. |
1995-01-19 |
2023-08-12 |
Not clear |
| G van den Berg, M Frölich, J D Veldhuis, F Roelfsem. Growth hormone secretion in recently operated acromegalic patients. The Journal of clinical endocrinology and metabolism. vol 79. issue 6. 1995-01-12. PMID:7989479. |
in patients with active acromegaly, about 50% of the gh was secreted in a nonpulsatile fashion. |
1995-01-12 |
2023-08-12 |
human |
| H Watanobe, S Habu, R Nasushita, K Takeb. Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone. Neuropeptides. vol 27. issue 2. 1995-01-10. PMID:7991070. |
lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (gh) responses in acromegaly: comparison with the gh responses to thyrotropin-releasing hormone and gh-releasing hormone. |
1995-01-10 |
2023-08-12 |
Not clear |
| H Watanobe, S Habu, R Nasushita, K Takeb. Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone. Neuropeptides. vol 27. issue 2. 1995-01-10. PMID:7991070. |
we examined whether the cholinergic mechanism is involved in the paradoxical gh responses to vasoactive intestinal peptide (vip) and peptide histidine methionine (phm) in acromegaly. |
1995-01-10 |
2023-08-12 |
Not clear |
| H Watanobe, S Habu, R Nasushita, K Takeb. Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone. Neuropeptides. vol 27. issue 2. 1995-01-10. PMID:7991070. |
although the lack of cholinergic involvement in the trh-induced gh release in acromegaly is confirmatory to previous reports, the same results with the vip- and phm-induced gh release are novel. |
1995-01-10 |
2023-08-12 |
Not clear |
| H Watanobe, S Habu, R Nasushita, K Takeb. Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone. Neuropeptides. vol 27. issue 2. 1995-01-10. PMID:7991070. |
the present study may suggest that in acromegaly the physiological gh response is mediated by the cholinergic mechanism, but the paradoxical ones are not. |
1995-01-10 |
2023-08-12 |
Not clear |
| C P Aström, W Trojabor. [Effect of growth hormone on sleep energy]. Ugeskrift for laeger. vol 156. issue 40. 1995-01-03. PMID:7985277. |
the acromegaly was verified biochemically by measuring basal plasma gh concentration and plasma gh during hyperglycaemia as well as insulin-like growth factor. |
1995-01-03 |
2023-08-12 |
Not clear |